Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of around 20 different brokers. See the list of analysts and their contact details here

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.  

 ucb

UCB FY Consensus Product Sales Estimates (Average)

In € million 2021a 2022e 2023e 2024e  2025e  2026e  2027e Peak Sales NPV*
Product Portfolio                  
Cimzia 1,841 1,976 2,036 1,940 1,882 1,438 1,214   4,872
Vimpat 1,549 969 619 519 453 399 366   1,697
Keppra  970 752 665 606 564 523 466   2,248
Briviact 355 436 508 571 618 566 384 621 1,632
Neupro 307 280 250 215 194 178 170   706
Evenity**   652 797 938 1,061 1,115 1,091 1,186 2,103
Nayzilam 57 84 107 128 144 147 142 176 497
Bimzelx 4 146 477 933 1,391 1,856 2,341 3,220 8,015
Fintepla   99 253 372 486 587 608 818 2,061
Potential new Products
(global sales, non-risk adj.)
                 
Zilucoplan   0 67 188 320 462 566 995 2,430
Rozanolixizumab    0 42 133 258 411 515 1,159 2,145
Dapimab   0 0 4 51 162 226    
Staccato alprazolam   0 1 17 58 100 140 246 572 
Bepranemab   0 0 13 43 63 79    

*If cell blank: not sufficient data available
**global sales 

UCB FY Consensus Earnings Estimates (Average)

In € million 2021a 2022e 2023e 2024e  2025e 2026e
Net Sales 5,471   5,044  5,257  5,789 6,291  6,663
Revenue 5,777   5,315 5,523  6,054  6,538  6,906
Adjusted EBIT 1,318   1,017 1,130  1,463 1,799   1,979
Adjusted EBITDA 1,641   1,380 1,545  1,919  2,274 2,457 
Net Profit*  1.058  773  901  1,193 1,510  1,684 
Core EPS (€) 6.49  4.99 5.58 7.15 8.74  9.56 

*attributable to UCB shareholders  

UCB FY Consensus Product Sales Estimates (Median)

In € million 2021a 2022e 2023e 2024e  2025e  2026e  2027e Peak Sales NPV
Product Portfolio                  
Cimzia 1,841 1,981 2,050 1,906 1,662 1,398 1,200   4,850
Vimpat 1,549 987 586 516 456 406 386   1,665
Keppra  970 789 683 594 541 490 451   1,945
Briviact 355 437 509 572 625 609 389 641 1,664
Neupro 307 287 256 215 201 185 172   642
Evenity**   668 807 939 1,077 1,119 1,095 1,173 2,240
Nayzilam 57 85 108 127 143 146 140 156 550
Bimzelx 4 150 454 877 1,359 1,832 2,340 3,284 7,814
Fintepla   102 253 366 458 584 632 791 2,000
Potential new Products**
(global sales, non-risk adj.)
                 
Zilucoplan   0 50 172 332 488 640 1,080 2,335
Rozanolixizumab    0 32 145 268 352 440 1,080 1,953
Dapimab   0 0 0 50 180 225    
Staccato alprazolam   0 0 18 42 75 118 208 500 
Bepranemab   0 0 0 27 27 56    

*If cell blank: not sufficient data available
**global sales   

UCB FY Consensus Earnings Estimates (Median)

In € million 2021a 2022e 2023e 2024e  2025e 2026e
Net Sales 5,471   5,037  5,276  5,835 6,401  6,699
Revenue 5,777   5,310 5,501  6,104  6,631  6,941
Adjusted EBIT 1,318   1,023 1,131  1,462 1,803   2,055
Adjusted EBITDA 1,641   1,381 1,563  1,934  2,262 2,518 
Net Profit*  1.058  760  901  1,183 1,512  1,742 
Core EPS (€) 6.49  5.07 5.66 7.21 8.71  9.79 

*attributable to UCB shareholders

Downloads:
UCB FY Consensus (Excel)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)

Last updated 24 March 2022



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.